摘要
目的观察疏血通对慢性肾小球肾炎患者肾小管间质损害的防治作用。方法应用比色法及乳胶凝集法分别检测26例慢性肾小球肾炎常规治疗组患者和27例疏血通治疗组慢性肾小球性肾炎患者治疗前后,以及23例健康对照组尿胱蛋白酶抑制剂C(Cyst C)、尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)、尿纤维蛋白降解产物(FDP)的水平。结果慢性肾小球性肾炎患者尿FDP水平升高,尿Cyst C为(0.61±0.10)μg/m L,NAG为(19.86±3.07)U/L,较健康对照组明显升高(P<0.01)。疏血通治疗后,尿NAG降为(12.55±3.00)U/L、尿Cyst C降为(0.36±0.08)μg/m L,尿FDP水平均降低。结论疏血通通过抗凝作用对慢性肾小球肾炎患者肾小管间质损害起到防治作用。
Objective To observe the protective effect of Shuxuetong on the renal tubulointerstitial lesion in chronic glomerular nephritis. Methods The levels of NAG and FDP in urine of the 26 cases of chronic glomerular nephritis treated with regular therapy, 27 cases treated with Shuxuetong and 23 cases of healthy people as control group were measured by use of colorimetry and latex coagulation test. Results The levels of urinary NAG（19.86±3.07）U/L, Cyst C（0. 61 ±0. 10）μg/mL, and FDP were significantly higher in chronic glomerular nephrits than those in the control group, and the levels of urinary NAG（12. 55 ±3.00）U/L. Cyst C（0. 36 ±0.08）μg/mL and FDP in patients treated with Shuxuetong were lower than those in patients with regular therapy. Conclusion Shuxuetong injection may play a preventive role on the renal tubulointerstitial lesion in chronic glomerular nephritis by anticoagulation.
出处
《中国药业》
CAS
2015年第19期27-28,共2页
China Pharmaceuticals
